Astria Therapeutics, Inc. (ATXS) Stock Ticker
Market factors today
Unlock the full ATXS picture
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
ATXS stock facts
| Ticker symbol | ATXS |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $718.1M |
| CEO | Jill C. Milne |
| Employees | 78 |
| Headquarters | Boston, MA, US |
| IPO date | 2015-06-25 |
| Website | www.astriatx.com |
What you can see for ATXS on Tickr
Live ATXS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ATXS report.
Rankings
FAQ
What is the ticker symbol for Astria Therapeutics, Inc.?
The ticker symbol for Astria Therapeutics, Inc. is ATXS, listed on the NASDAQ Global Market.
What is ATXS?
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein.…